UTHR
United Therapeutics Corporation
242.13
USD
This page is just a preview of the data found in TrendSpider’s full version
United Therapeutics Corporation stock is up 9.21% since 30 days ago. The next earnings date is Feb 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 64% of the previous 24 December’s closed higher than November. In the last 8 Unusual Options Trades, there were 6 PUTs, 2 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 25 Oct 18:38 | 17 Nov, 2023 | 220.00 | 350 | ||
| 01 Nov 16:13 | 17 Nov, 2023 | 210.00 | 1 | ||
| 17 Nov 19:04 | 16 Feb, 2024 | 250.00 | 24 | ||
| 22 Nov 18:02 | 17 May, 2024 | 250.00 | 0 | ||
| 06 Dec 16:51 | 17 May, 2024 | 290.00 | 0 | ||
| 06 Dec 18:26 | 17 May, 2024 | 290.00 | 0 | ||
| 06 Dec 18:40 | 17 May, 2024 | 290.00 | 0 | ||
| 06 Dec 20:42 | 17 May, 2024 | 280.00 | 0 |
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
